VERAXA Biotech Appoints Dr. Christoph Erkel as CSO to Advance BiTAC(R) Cancer Therapy Platform

VERAXA Biotech AG (NASDAQ: VRXA) has appointed antibody therapeutics specialist Dr. Christoph Erkel as Chief Scientific Officer, reinforcing the company's focus on advancing its proprietary BiTAC(R) technology platform as it prepares its lead oncology programs for clinical development. The leadership change comes as the company progresses its diversified oncology pipeline, which includes conditionally active T-cell engagers, bispecific ADCs, and other engineered antibody therapeutics.

Dr. Erkel previously served as Vice President of Research & Development, where he oversaw development of VERAXA's antibody therapeutics portfolio. In his new role, he will lead scientific strategy across the company's BiTAC(R) platforms and broader oncology pipeline, directing efforts to accelerate product candidates toward clinical trials. The announcement follows recent regulatory feedback from Germany's Paul-Ehrlich-Institute, which provided additional clarity for the development of VERAXA's lead BiTAC(R)-TCE program.

The company is building a diversified oncology pipeline designed to improve efficacy while reducing treatment-related toxicity, a key focus for next-generation immunotherapies. VERAXA's proprietary BiTAC(R) technology platform enables the design of conditionally active bispecific T-cell engagers that aim to target tumors more precisely. Investors are closely watching companies developing such novel approaches to cancer therapy.

For more information on VERAXA Biotech, visit the company's newsroom at https://ibn.fm/VRXA.

This appointment underscores VERAXA's commitment to strengthening its scientific leadership as it moves toward clinical development. The company's pipeline includes several programs that leverage the BiTAC(R) platform, with the goal of addressing unmet needs in oncology. Dr. Erkel's expertise in antibody therapeutics is expected to drive the advancement of these candidates.

The biotechnology sector continues to see significant interest in next-generation immunotherapies, and VERAXA is positioning itself to be a key player in this space. With a clear regulatory pathway and strengthened leadership, the company is poised to make progress in its mission to design novel cancer therapies.